The CRO That Solves
Oncology Trial Challenges.
Reliable, flexible, and built for global trials — Biorasi brings cancer therapies to patients faster.
Why Biorasi
For Oncology?
When cancer trials require strategic precision, sponsors turn to Biorasi. We combine oncology-specific experience, global reach, and agile execution to overcome barriers and hit milestones on time, every time.
Subspecialties
- Solid Tumors
- Hematologic Malignancies
- Rare Cancers
Proof of Performance
- 24 Oncology Studies
- 19 Indications
- 194 Sites Activated
- 1,146 Patients Enrolled
THE BIORASI ADVANTAGE
ONCOLOGY EXPERIENCE
Proven strategies even in rare and hard-to-reach populations
REGULATORY EXPERTISE
Oncology-focused regulatory insights with FDA, EMA, and global compliance
GLOBAL REACH
Access to patients and clinical sites across 48 countries
FROM OUR PARTNERS
Hyun Kim
VP Clinical Operations, AOBiome Therapeutics
I cannot think of anyone else to work with other than Biorasi
Our relationship is not just a Sponsor-CRO relationship. It is really a true partnership.
Supriya Lala Kundu
Research Analyst, Best Practices, Frost & Sullivan
Biorasi provides the necessary framework, capability, scalability, and flexibility for protocol design and enhancement as per the evolving regulatory environment, early in the clinical trial process, to seamlessly progress the trial. An expert in digital therapeutic trials, the company flexibly manages the trial complexity, clinical validation, regulatory approval, and payer reimbursement.
Amy Beasley
Former Manager of Clinical Operations, Savara Pharmaceuticals
Biorasi far exceeds other vendors.
“For flexibility, nimbleness, and willingness to partner with us to solve our problems, Biorasi far exceeds other vendors. They give attention and detail to smaller-sized companies like us, and provide a great strategic value.”
Mary Varhgese Presti
Vice President, Life Sciences, IBM Watson Health
Biorasi and IBM Health: Greater Efficiency and Precision
Biorasi has been at the forefront of e-clinical innovation and has demonstrated continued leadership in leveraging the ICD platform. We are proud to support Biorasi’s ongoing effort to bring greater efficiency and precision to the clinical trial process, particularly in emerging areas such as digital therapeutics, virtual trials, and precision medicine.
